The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer (2019)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1016/j.oraloncology.2019.09.013
- Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO; POLIMORFISMO; CARCINOMA DE CÉLULAS ESCAMOSAS; SEQUENCIAMENTO GENÉTICO; QUIMIOTERAPIA; ANTINEOPLÁSICOS; PROTEÍNAS DE TRANSPORTE; GENÓTIPOS
- Agências de fomento:
- National Counsel of Technological and Scientific Development (CNPq) scholarshipNational Council for Scientific and Technological Development (CNPq)
- CNPqNational Council for Scientific and Technological Development (CNPq)
- CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)National Council for Scientific and Technological Development (CNPq) [473210/2012-6]
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Oral oncology
- ISSN: 1368-8375
- Volume/Número/Paginação/Ano: v. 98, p. 48-52, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MARCHI, Pedro De et al. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Oral oncology, v. 98, p. 48-52, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.oraloncology.2019.09.013. Acesso em: 12 jun. 2024. -
APA
Marchi, P. D., Melendez, M. E., Laus, A. C., Kuhlmann, P. A., Carvalho, A. C. de, Arantes, L. M. R. B., et al. (2019). The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Oral oncology, 98, 48-52. doi:10.1016/j.oraloncology.2019.09.013 -
NLM
Marchi PD, Melendez ME, Laus AC, Kuhlmann PA, Carvalho AC de, Arantes LMRB, Evangelista AF, Andrade ES, Castro Junior G de C, Reis RM. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer [Internet]. Oral oncology. 2019 ; 98 48-52.[citado 2024 jun. 12 ] Available from: https://doi.org/10.1016/j.oraloncology.2019.09.013 -
Vancouver
Marchi PD, Melendez ME, Laus AC, Kuhlmann PA, Carvalho AC de, Arantes LMRB, Evangelista AF, Andrade ES, Castro Junior G de C, Reis RM. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer [Internet]. Oral oncology. 2019 ; 98 48-52.[citado 2024 jun. 12 ] Available from: https://doi.org/10.1016/j.oraloncology.2019.09.013 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
Informações sobre o DOI: 10.1016/j.oraloncology.2019.09.013 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
